Pregnant Patients and FCM-Associated Hypophosphatemia
Pregnant individuals receiving ferric carboxymaltose (FCM) do NOT appear to be at risk for hypophosphatemia, making them a unique exception to the well-documented hypophosphatemia risk seen in other patient populations. 1111
Key Evidence
The most recent and authoritative 2025 Lancet Haematology guidelines explicitly state: "Notably, pregnant individuals receiving this formulation do not appear to be at risk for hypophosphatemia." 1 This represents a critical distinction from the general population, where FCM causes hypophosphatemia in approximately 50-75% of patients receiving standard two-dose infusions.
Supporting Research Data
Prospective observational study (2024): Among 22 pregnant women treated with FCM, only 3 cases (13.6%) of maternal hypophosphatemia occurred, with just 1 case (4.5%) of neonatal hypophosphatemia. After adjustment for confounding factors, IV iron administration had no impact on cord blood phosphate levels (p=0.919). 2
Controlled study (2018): In pregnant subjects receiving 1g FCM, serum phosphate reached its nadir at Day 7 but recovered by Day 21—significantly faster than in CKD patients (Day 42) or controls. 3
Clinical Context and Mechanism
Why Pregnancy is Protective
While the exact mechanism remains unclear, pregnancy appears to confer protection against FCM-induced hypophosphatemia despite the drug's well-established effect on fibroblast growth factor 23 (FGF23) and urinary phosphate excretion in non-pregnant populations. This may relate to:
- Altered phosphate homeostasis during pregnancy
- Increased intestinal phosphate absorption
- Hormonal influences on renal phosphate handling
Contrast with General Population
In non-pregnant adults, FCM consistently causes:
- Hypophosphatemia rates of 50-75% 11
- Severe hypophosphatemia (<1.0 mg/dL) in some cases 1
- Persistent hypophosphatemia lasting weeks to months 14
- Potential complications including osteomalacia and pseudofractures with repeated dosing 14
Practical Implications
For pregnant patients with iron deficiency anemia:
- FCM can be used safely without routine phosphate monitoring 1
- The 2025 guidelines recommend IV iron (where acceptable) in the second trimester and suggest offering it over oral iron in the third trimester 11
- Single infusion provides rapid iron repletion with improved hemoglobin response compared to oral iron 56
Important caveats:
- This protection applies specifically to pregnancy; postpartum patients should be considered at standard risk
- The FDA label notes that severe hypersensitivity reactions can cause fetal bradycardia, particularly in second and third trimesters 77
- While hypophosphatemia risk is minimal, standard monitoring for other adverse events remains appropriate
When to Reconsider FCM
For patients requiring repeated courses of IV iron (even in pregnancy), consider alternative formulations like ferric derisomaltose, which shows significantly lower hypophosphatemia rates (3.9% vs 47% with FCM) in general populations. 48 However, the pregnancy-specific data suggests this concern is less relevant during gestation itself.